EGFR and neoplasm: Nimotuzumab is a humanised IgG1 monoclonal antibody that acts on the extracellular structural domain of EGFR and exerts its antitumour effects mainly by inhibiting tumour cell proliferation, anti-angiogenesis, and promoting apoptosis (10).